Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial

Primary endpoints successfully met Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment 0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg Excellent safety profile Paves the way for ... Biopharmaceuticals, Drug Delivery, Endocrinology Oramed Pharmaceuticals, oral insulin, insulin, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news